Anzeige
Mehr »
Login
Dienstag, 31.03.2020 Börsentäglich über 12.000 News von 622 internationalen Medien
Noch unter dem Radar: Diese Goldaktie mit massivem Kurspotenzial müssen Sie haben
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ARHW ISIN: US8673287004 Ticker-Symbol: RYIP 
Tradegate
26.03.20
09:19 Uhr
0,376 Euro
-0,032
-7,84 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SUNESIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SUNESIS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,362
0,410
11:46
0,362
0,410
11:51

Aktuelle News zur SUNESIS PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSunesis Pharmaceuticals - 400mg data similar to previous cohort111On 18 March, Sunesis released the first assessments of the 400mg cohort in its ongoing dosing study of vecabrutinib for B-cell malignancies. Two (of three) patients in this cohort showed stable disease...
► Artikel lesen
SUNESIS PHARMACEUTICALS Aktie jetzt für 4€ handeln
18.03.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report-
12.03.Sunesis Pharmaceuticals - Multiple upcoming readouts on vecabrutinib721Sunesis provided an update on its ongoing dosing study of vecabrutinib on its 2019 earning conference call: the first response assessment for the 400mg cohort will be available later in March and the...
► Artikel lesen
11.03.Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript4
10.03.SUNESIS PHARMACEUTICALS INC - 10-K, Annual Report-
10.03.BRIEF-Sunesis Pharmaceuticals Reports Qtrly Loss Per Share $0.05-
10.03.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report-
03.03.BRIEF-Sunesis Pharmaceuticals Says Estimates That Cash, Cash Equivalents, Restricted Cash, Marketable Securities As Of Dec 31, 2019 Was About $34.6 Million3
03.03.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report-
13.01.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report7
07.01.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report2
17.12.19SUNESIS PHARMACEUTICALS INC - 8-K, Current Report4
16.12.19Sunesis Pharmaceuticals - 300mg suggests activity, but higher doses needed175Sunesis reported updated data from the dosing portion of its ongoing Phase Ib/II study of vecabrutinib for chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The key data on the highest...
► Artikel lesen
11.12.19Sunesis Pharmaceuticals (SNSS) Investor Presentation - Slideshow4
09.12.19Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of Biopharma25
06.12.19SUNESIS PHARMACEUTICALS INC - 8-K, Current Report6
05.12.19Sunesis Pharma down 24% on disappointing vecabrutinib data7
05.12.19Sunesis Pharmaceuticals, Inc.: Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib ...3
14.11.19Sunesis Pharmaceuticals - Insight into the future of SNS-510807Sunesis recently presented a poster on the preclinical findings of its PDK1 inhibitor SNS-510. Surprisingly, researchers found that the drug was most active in cancer cell lines with mutations in the...
► Artikel lesen
12.11.19SUNESIS PHARMACEUTICALS INC - 10-Q, Quaterly Report-
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1